FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281569449> ?p ?o ?g. }

• W4281569449 endingPage "682" @default.
• W4281569449 startingPage "682" @default.
• W4281569449 abstract "Data are limited regarding the risk of cerebrovascular ischemic events and major bleeding in patients with atrial fibrillation (AF) and recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI).Determine the efficacy and safety of apixaban or vitamin K antagonists (VKA) and aspirin or placebo according to prior stroke, transient ischemic attack (TIA), or thromboembolism (TE).In this prospective, multicenter, 2-by-2 factorial, randomized clinical trial, post hoc parallel analyses were performed to compare randomized treatment regimens according to presence or absence of prior stroke/TIA/TE using Cox proportional hazards models. Patients with AF, recent ACS or PCI, and planned use of P2Y12 inhibitors for 6 months or longer were included; 33 patients with missing data about prior stroke/TIA/TE were excluded.Apixaban (5 mg or 2.5 mg twice daily) or VKA and aspirin or placebo.Major or clinically relevant nonmajor (CRNM) bleeding.Of 4581 patients included, 633 (13.8%) had prior stroke/TIA/TE. Patients with vs without prior stroke/TIA/TE were older; had higher CHA2DS2-VASC and HAS-BLED scores; and more frequently had prior bleeding, heart failure, diabetes, and prior oral anticoagulant use. Apixaban was associated with lower rates of major or CRNM bleeding and death or hospitalization than VKA in patients with (hazard ratio [HR], 0.69; 95% CI, 0.46-1.03) and without (HR, 0.68; 95% CI, 0.57-0.82) prior stroke/TIA/TE. Patients without prior stroke/TIA/TE receiving aspirin vs placebo had higher rates of bleeding; this difference appeared less substantial among patients with prior stroke/TIA/TE (P = .01 for interaction). Aspirin was associated with numerically lower rates of death or ischemic events than placebo in patients with (HR, 0.71; 95% CI, 0.42-1.20) and without (HR, 0.93; 95% CI, 0.72-1.21) prior stroke/TIA/TE (not statistically significant).The safety and efficacy of apixaban compared with VKA was consistent with the AUGUSTUS findings, irrespective of prior stroke/TIA/TE. Aspirin increased major or CRNM bleeding, particularly in patients without prior stroke/TIA/TE. Although aspirin may have some benefit in patients with prior stroke, our findings support the use of apixaban and a P2Y12 inhibitor without aspirin for the majority of patients with AF and ACS and/or PCI, regardless of prior stroke/TIA/TE status.ClinicalTrials.gov Identifier: NCT02415400." @default.
• W4281569449 created "2022-05-27" @default.
• W4281569449 creator A5011747612 @default.
• W4281569449 creator A5014449865 @default.
• W4281569449 creator A5016139987 @default.
• W4281569449 creator A5026937673 @default.
• W4281569449 creator A5027053307 @default.
• W4281569449 creator A5027138068 @default.
• W4281569449 creator A5032514171 @default.
• W4281569449 creator A5041130917 @default.
• W4281569449 creator A5042045701 @default.
• W4281569449 creator A5043643766 @default.
• W4281569449 creator A5047187243 @default.
• W4281569449 creator A5053194091 @default.
• W4281569449 creator A5057062433 @default.
• W4281569449 creator A5061098195 @default.
• W4281569449 creator A5067237537 @default.
• W4281569449 creator A5067347864 @default.
• W4281569449 creator A5067928315 @default.
• W4281569449 creator A5071420746 @default.
• W4281569449 date "2022-07-01" @default.
• W4281569449 modified "2023-10-18" @default.
• W4281569449 title "Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke" @default.
• W4281569449 cites W2018856451 @default.
• W4281569449 cites W2108745446 @default.
• W4281569449 cites W2110258159 @default.
• W4281569449 cites W2140501627 @default.
• W4281569449 cites W2157459435 @default.
• W4281569449 cites W2162586165 @default.
• W4281569449 cites W2376943477 @default.
• W4281569449 cites W2523455750 @default.
• W4281569449 cites W2556417520 @default.
• W4281569449 cites W2749929702 @default.
• W4281569449 cites W2794420720 @default.
• W4281569449 cites W2921724943 @default.
• W4281569449 cites W2972299172 @default.
• W4281569449 cites W2987999111 @default.
• W4281569449 cites W2989714602 @default.
• W4281569449 cites W3009038287 @default.
• W4281569449 cites W4210812992 @default.
• W4281569449 cites W4232034913 @default.
• W4281569449 doi "https://doi.org/10.1001/jamacardio.2022.1166" @default.
• W4281569449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35612866" @default.
• W4281569449 hasPublicationYear "2022" @default.
• W4281569449 type Work @default.
• W4281569449 citedByCount "2" @default.
• W4281569449 countsByYear W42815694492023 @default.
• W4281569449 crossrefType "journal-article" @default.
• W4281569449 hasAuthorship W4281569449A5011747612 @default.
• W4281569449 hasAuthorship W4281569449A5014449865 @default.
• W4281569449 hasAuthorship W4281569449A5016139987 @default.
• W4281569449 hasAuthorship W4281569449A5026937673 @default.
• W4281569449 hasAuthorship W4281569449A5027053307 @default.
• W4281569449 hasAuthorship W4281569449A5027138068 @default.
• W4281569449 hasAuthorship W4281569449A5032514171 @default.
• W4281569449 hasAuthorship W4281569449A5041130917 @default.
• W4281569449 hasAuthorship W4281569449A5042045701 @default.
• W4281569449 hasAuthorship W4281569449A5043643766 @default.
• W4281569449 hasAuthorship W4281569449A5047187243 @default.
• W4281569449 hasAuthorship W4281569449A5053194091 @default.
• W4281569449 hasAuthorship W4281569449A5057062433 @default.
• W4281569449 hasAuthorship W4281569449A5061098195 @default.
• W4281569449 hasAuthorship W4281569449A5067237537 @default.
• W4281569449 hasAuthorship W4281569449A5067347864 @default.
• W4281569449 hasAuthorship W4281569449A5067928315 @default.
• W4281569449 hasAuthorship W4281569449A5071420746 @default.
• W4281569449 hasBestOaLocation W42815694491 @default.
• W4281569449 hasConcept C126322002 @default.
• W4281569449 hasConcept C127413603 @default.
• W4281569449 hasConcept C142724271 @default.
• W4281569449 hasConcept C164705383 @default.
• W4281569449 hasConcept C204787440 @default.
• W4281569449 hasConcept C207103383 @default.
• W4281569449 hasConcept C27081682 @default.
• W4281569449 hasConcept C2776301958 @default.
• W4281569449 hasConcept C2777628954 @default.
• W4281569449 hasConcept C2777698277 @default.
• W4281569449 hasConcept C2778661090 @default.
• W4281569449 hasConcept C2779161974 @default.
• W4281569449 hasConcept C2780400711 @default.
• W4281569449 hasConcept C2780638905 @default.
• W4281569449 hasConcept C2780645631 @default.
• W4281569449 hasConcept C44249647 @default.
• W4281569449 hasConcept C45393284 @default.
• W4281569449 hasConcept C500558357 @default.
• W4281569449 hasConcept C71924100 @default.
• W4281569449 hasConcept C78519656 @default.
• W4281569449 hasConceptScore W4281569449C126322002 @default.
• W4281569449 hasConceptScore W4281569449C127413603 @default.
• W4281569449 hasConceptScore W4281569449C142724271 @default.
• W4281569449 hasConceptScore W4281569449C164705383 @default.
• W4281569449 hasConceptScore W4281569449C204787440 @default.
• W4281569449 hasConceptScore W4281569449C207103383 @default.
• W4281569449 hasConceptScore W4281569449C27081682 @default.
• W4281569449 hasConceptScore W4281569449C2776301958 @default.
• W4281569449 hasConceptScore W4281569449C2777628954 @default.
• W4281569449 hasConceptScore W4281569449C2777698277 @default.
• W4281569449 hasConceptScore W4281569449C2778661090 @default.

• next